Home

Akero Therapeutics

Akero Therapeutics to Present Efruxifermin (EFX) Results Showing Histologic Improvement in EFX-Treated F4 Cirrhotic Patients as a Late-Breaker Oral Presentation at the 2021 International Liver Congress. 06-01-2021 Akero Therapeutics to Present at the Jefferies Virtual Healthcare Conference. 05-28-2021 Events More events are coming soon. Print; RSS Feeds; Email Alerts; Contact IR; About; R & D.

AKERO THERAPEUTICS AKTIE Aktienkurs Kurs (A2PLNP

Akero Therapeutics Aktie (A2PLNP, US00973Y1082, AKRO) Akero Therapeutics Aktie im Überblick: Realtimekurs, Chart, Fundamentaldaten, sowie aktuelle Nachrichten und Meinungen. Um die volle.. AKERO THERAPEUTICS Aktie jetzt für 0€ handeln: 02.06. Akero Therapeutics, Inc. - 8-K, Current Report: 1: SEC Filings: 28.05. Akero Therapeutics to Present at the Jefferies Virtual Healthcare. R & D. Our R&D is singularly focused on developing medicines to reverse the escalating NASH epidemic. NASH is a disease involving the whole body, requiring treatment of the imbalanced metabolism, as well as acting directly on the liver

Investors Akero Therapeutics, Inc

  1. Profil Akero Therapeutics Die Akero Therapeutics Inc Registered Shs Accred Inv Aktie wird unter der ISIN US00973Y1082 an den Börsen Frankfurt, Stuttgart, Berlin, NASDAQ, Bats und NDB gehandelt...
  2. (EFX) for the treatment of nonalcoholic steatohepatitis (NASH), which requires rigorous evaluation of the safety and efficacy of EFX in clinical trials. If these trials provide substantial evidence that EFX is safe and effective for treatment of NASH, we will seek marketing approvals from.
  3. Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, EFX, an engineered Fc-FGF21 fusion protein, is currently being evaluated in a Phase 2b clinical trial as a potential treatment for NASH. Akero is headquartered in South San.
  4. Akero Therapeutics Inc. ist ein Unternehmen für kardio-metabolische nicht-alkoholische Steatohepatitis (NASH). Das Unternehmen konzentriert sich auf die Entwicklung von Medikamenten, die das metabolische Gleichgewicht wiederherstellen und den allgemeinen Gesundheitszustand von Patienten mit NASH verbessern sollen
  5. Akero Therapeutics Aktie Branche: : ISIN: US00973Y1082 Kurs mit Realtime Chart Alle Entwicklungen, Kommentare und News auf BörsenNEWS.de live verfolgen

Akero Therapeutics Aktie (A2PLNP, US00973Y1082, AKRO

  1. About Akero Therapeutics Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance to improve overall health. The company's lead product candidate, AKR-001, is currently being evaluated in an ongoing Phase 2a clinical trial. Akero Therapeutics is headquartered in San Francisco, CA. For.
  2. Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs...
  3. Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, EFX, an engineered Fc-FGF21 fusion protein, is currently being evaluated in Phase 2 clinical trials as a potential treatment for NASH. Akero is headquartered in South San.
  4. Akero Therapeutics Firmenprofil ) Akero Therapeutics, Inc, ein Biotechnologieunternehmen im klinischen Stadium, befasst sich mit der Entwicklung und Vermarktung von Therapien für schwere Stoffwechselerkrankungen. Sein Hauptproduktkandidat ist AKR - , die sich in der klinischen Phase IIa-Studie zur Behandlung von alkoholfreiem Alkohol befindet Steatohepatitis-Krankheit. Das Unternehmen war.
  5. About Akero TherapeuticsAkero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any..

AKERO THERAPEUTICS, INC. : Kurs, Charts, Kurse, Empfehlungen, Fundamentaldaten, Echtzeitnews und Analysen der Aktie AKERO THERAPEUTICS, INC. | A2PLNP | US00973Y1082. Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies Akero Therapeutics started at outperform with $35 stock price target at Evercore ISI Jul. 15, 2019 at 7:42 a.m. ET by Tomi Kilgore S&P 500 closes at historic peak after Fed adopts easy-money postur Akero Therapeutics Initiates Phase 2b HARMONY Study of Efruxifermin (EFX) for the Treatment of NASH | Akero Therapeutics, Inc 22 Mar 2021 Akero Therapeutics plans phase IIb SYMMETRY trial for Non-alcoholic steatohepatitis in second half of 2021 ; 22 Mar 2021 Updated safety and efficacy from phase IIb BALANCED trial in Non-alcoholic steatohepatitis released by Akero Therapeutics ; Subscriber content You need to be a logged in subscriber to view this content. If your organization has a subscription then there are.

Akero Therapeutics News: auf dieser Seite finden Sie alle Akero Therapeutics News und Nachrichten zur Akero Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Akero. Historische Kurse AKERO THERAPEUTICS - Ein Überblick über die Schlusskurse am Börsenplatz FSE inklusive Tageshoch, Tagestief und Volumen der AKERO THERAPEUTICS Aktie. Das Datum ist frei wählbar

Akero Therapeutics to Announce New Data from an Evaluation of Efruxifermin (EFX) in Cirrhotic NASH (F4) Patients 16.03.21 Akero Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Result Akero Therapeutics Aktie: WKN A2PLNP - ISIN US00973Y1082 - Aktueller Aktienkurs, Charts, Nachrichten und Termine zu Akero Therapeutics

View Akero Therapeutics, Inc. AKRO investment & stock information. Get the latest Akero Therapeutics, Inc. AKRO detailed stock quotes, stock data, Real-Time ECN, charts, stats and more AKERO THERAPEUTICS INC. (A2PLNP | US00973Y1082) mit aktuellem Aktienkurs, Charts, News und Analysen Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA Akero Therapeutics, Inc. (AKRO) registered a -4.64% downside in the last session and has traded in the red over the past 5 sessions. The stock spiked 5.11% in intraday trading to $28.37 this Tuesday, May 18, hitting a weekly high. The stock's 5-day price performance is -4.57%, and it has moved by -4.4% in 30 days. Despite these dips, the overall price performance for the year is 4.34%. The. Find out all the key statistics for Akero Therapeutics, Inc. (AKRO), including valuation measures, fiscal year financial statistics, trading record, share statistics and more

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins. Akero Therapeutics Aktie: Hier finden Sie den Akero Therapeutics Aktienkurs aktuell und ausserdem weitere Informationen wie den Akero Therapeutics Char Akero Therapeutics Inc Veränderung Vortag: 0.89%, Aktueller Kurs: 22.8 € Diese Seite verwendet Cookies. Für eine vollständige Nutzung von sharewise sind Cookies zwingend notwendig Akero Therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. Akero's lead clinical program, AKR-001, is a long-acting Fc fusion modified FGF21 agonist and potential best-in-class treatment for NASH. AKR-001 builds upon two decades of work on FGF21 biology and is designed to affect.

AKERO THERAPEUTICS AKTIEN News A2PLNP Nachrichte

Akero Therapeutics (NASDAQ:AKRO) Price Target and Consensus Rating. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are. Akero Therapeutics, Inc. Common Stock (AKRO) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets

Akero Therapeutics may lead in the NASH market in future. In our previous assessment, we compared 13 NASH drug candidates, and our favorite was AK-001 of Akero Therapeutics (NASDAQ: AKRO ) Akero Therapeutics Inc made the announcement of pricing on its initial public offering at $16.00 per share. Previous estimates had placed the pricing between $14 and $16 and it opened with the higher estimate. Trading commenced with the first day of the initial public offering on June 20, 2019. Akero offered 5,750,000 shares of its common stock. The company is registered as a publicly-traded. Akero Therapeutics Inc. is a cardio-metabolic non-alcoholic steatohepatitis (NASH) company. The Company is focused on developing medicines designed to restore metabolic balance and improve the. Handelsplätze und Kurse zu Akero Therapeutics auf einen Blick Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren. Nasdaq 272.458 Stk AKERO THERAPEUTICS, INC. (A2PLNP) 26.02. AKERO THERAPEUTICS, INC. : Guggenheim behält seine Kaufempfehlung bei. Die fundamentale Situation des Unternehmens hat sich bei einem kurzfristigen Anlagehorizont verschlechtert. Die Analysten sind im Hinblick auf diese Aktie positiv gestimmt

R&D Akero Therapeutics Research and Development Aker

Akero Therapeutics (NASDAQ: AKRO) shares opened at $16.16 Thursday morning after pricing of 5.75 million shares of common stock at $16.. Akero was founded in January 2017 and focuses on developing. Akero Therapeutics, Inc, a South San Francisco, California-based clinical-stage biotech, is planning a 5-million share IPO, with the offering estimated to be priced between $14 and $16, according. Akero Therapeutics is a leading NASH player and has a strong cash position with upcoming catalysts. The following is my analysis and investment thesis on AKRO stock In trading on Wednesday, shares of Akero Therapeutics Inc (Symbol: AKRO) crossed above their 200 day moving average of $29.40, changing hands as high as $29.60 per share. Akero Therapeutics Inc. Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced the presentation of additional data analysis from the Phase 2a BALANCED study at the Presiden

AKERO THERAPEUTICS Unternehmensprofil Informationen über

AKR-001 Akero Therapeutics Aker

  1. Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the.
  2. Quick Take. Akero Therapeutics has filed to raise gross proceeds of $75.0 million from a U.S. IPO, according to an S-1/A registration statement.The firm is developing a treatment for metabolic.
  3. Akero Therapeutics, Inc. operates as a biotechnology company. The Company discovers and develops medicines and therapies for metabolic diseases by restoring metabolic balance

Akero Announces Positive Histological Improvements in

Akero Therapeutics, Inc. operates as a cardio-metabolic nonalcoholic steatohepatitis company, which engages in developing pioneering medicines designed to restore metabolic balance and improve overall health. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular. Akero Therapeutics - Realtimekurse, Aktienkurse, Charts, Fundamentaldaten, Börsenplätze. Börse Geldkurs Briefkurs; Börse Stuttgart: 21,600€ 21,600€ 21,600.

AKERO THERAPEUTICS, INC

As Chief Scientific Officer at Akero Therapeutics, Inc., Timothy Rolph DPhil. made $2,133,664 in total compensation. Of this total $400,000 was received as a salary, $200,000 was received as a bonus, $1,533,664 was received in stock options, $0 was awarded as stock and $0 came from other types of compensation. This information is according to proxy statements filed for the 2019 fiscal year Akero Therapeutics lag 5,23 Prozent unter diesem Durchschnittswert. Die Unterperformance sowohl im Branchen- als auch im Sektorvergleich führt zu einem Sell-Rating in dieser Kategorie Aktuelle Aktienkurse der AKERO THERAPEUTICS INC, Börsenkurs 23,80 -1,65 %, Tief 23,800, Hoch 23,80 AKERO THERAPEUTICS INC. (A2PLNP | US00973Y1082): Überblick aller relevanten Fundamentalkennzahlen zum Unternehmen, wie z.B. Gewinn, Dividende, Cash-Flow und Umsatz Die Akero Therapeutics Inc Registered Shs Accred Inv Aktie wird unter der ISIN US00973Y1082 an den Börsen Frankfurt, Stuttgart, Berlin, NASDAQ, Bats und NDB gehandelt. Akero Therapeutics Inc Registered Shs Accred Inv ist ein Unternehmen aus den USA. Im gleichen Bereich tätige Unternehmen sind z.B. Akero Therapeutics

Analysts' Opinions Are Mixed on These Healthcare Stocks

Akero Therapeutics To Present At The 39th Annual J.P. Morgan Healthcare Conference. By Business Wire. Jan 4, 2021 4:05 PM EST. PRESS RELEASES Bei Akero Therapeutics handelt es sich um eine Biotechnologiefirma aus den USA, die sich bereits mit ihrem Lead-Kandidaten in der klinischen Phase 2 befindet (Start Q2/20). Die Rekrutierung der Patienten ist bereits abgeschlossen, sofern sich der Start durch Covid19 nicht verzögert. Das Hauptaugenmerk der Entwicklung liegt bei Stoffwechselerkrankungen, wie etwa Diabetes oder NASH. Bei NASH. In trading on Tuesday, shares of Akero Therapeutics Inc (Symbol: AKRO) crossed above their 200 day moving average of $30.62, changing hands as high as $30.99 per share. Akero Therapeutics Inc. Akero Therapeutics Aktien sind teuerer als andere, ähnliche Aktien. Aber diese hier aufgeführten Top 10 Aktien haben gute Finanzratings in der Branche Biotechnologie, Region USA. Die hier folgenden Aktien sind gute Anlage-Alternativen

SEC Filing | Akero Therapeutics, Inc

Akero Therapeutics • Aktie • / US00973Y108

  1. Akero Therapeutics is advancing new medicines designed to treat serious metabolic diseases by restoring metabolic balance. The company's lead compound is AKR-001, a novel long-acting FGF21 analogue. Akero plans to begin Phase 2 clinical studies of AKR-001 for the treatment of NASH
  2. AKERO THERAPEUTICS INC. (A2PLNP | US00973Y1082): Aktuelle Charts und umfangreiche Chartanalyse-Funktionen zu der AKERO THERAPEUTICS INC. Aktie
  3. g conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares
  4. Akero Therapeutics | 1.316 Follower auf LinkedIn Akero Therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. Akero's lead clinical program, AKR-001, is a long-acting Fc fusion modified FGF21 protein and potential best-in-class treatment for NASH
  5. Akero Therapeutics's top competitors include CymaBay, GENFIT SA and Blade Therapeutics. See the full list of Akero Therapeutics competitors, plus revenue, employees, and funding info on Owler, the world's largest community-based business insights platform

Press Release - Akero Therapeutics, Inc

Akero Therapeutics Inc (AKRO) Quote - XNAS Morningsta

  1. Akero Therapeutics Inc Registered Shares DL-,0001. WKN. A2PLNP. ISIN. US00973Y1082. Symbol. 0K4. Land. USA. Unternehmen. Akero Therapeutics
  2. g the treatment of non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases, today announced the completion of a $65 million Series A financing. The financing will be used to advance Akero's lead clinical program AKR-001, a novel, long-acting fibroblast growth factor 21 (FGF21) analogue. The round was co.
  3. Akero Therapeutics is providing treatment options for people with serious metabolic diseases like non-alcoholic steatohepatitis (NASH), a disease marked by inflammation in the liver and liver cell damage resulting in fibrosis, cirrhosis, liver failure and death. Business Areas: Metabolism, Therapeutics
  4. Akero Therapeutics (NASDAQ:AKRO) is one such company. Founded back in 2017 and only recently going public in mid-2019, Akero managed to attract a fair bit of excitement surrounding its only drug.
  5. (EFX), an analog of fibroblast growth factor 21 (FGF21). Efruxifer
  6. Zusammenfassung Diese Einschätzung wurde am 08.07.20 mit einem Endkurs von 34,20 € beendet. Mit einer Rendite von 14,77 % entwickelte sich die Einschätzung SELL nicht nach Plan. Biotechhunter hat eine Nachfolge-Einschätzung zu Akero Therapeutics Inc.Ebenfalls mit der Meinung, dass Akero Therapeutics Inc ein Sell ist. Biotechhunter hat 50% Zuversicht bei dieser Einschätzun
  7. , has been evaluated in a 16-week Phase 2a clinical trial, the BALANCED study. Akero Therapeutics is.

Akero Therapeutics Reports First Quarter 2021 Financial

About Akero Therapeutics Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance and improve overall health of NASH patients. The Company's lead product candidate, efruxifermin, has been evaluated in a 16-week Phase 2a clinical trial, the BALANCED study. Akero Therapeutics is. Akero Therapeutics to Announce Results for Week 12 Efficacy Endpoints from NASH Phase 2a BALANCED Study of AKR-001 Monday, 16 March 2020 yahoo. Should You Buy Akero Therapeutics Ahead of Earnings? prnewswire. Akero Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results Wednesday, 22 January 2020 benzinga. 82 Biggest Movers From Yesterday Monday, 13 January 2020 yahoo. Akero. Chart zur AKERO THERAPEUTICS INC Aktie. Alle Charts zu Ihren Aktien Akero Therapeutics, Inc. income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. Akero Therapeutics, Inc. annual reports of executive compensation and pay are most commonly found in the Def 14a documents. Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year. Other. Get the latest news and real-time alerts from Akero Therapeutics, Inc. (AKRO) stock at Seeking Alpha

Akero Therapeutics (NASDAQ: AKRO) wurde bei Zacks

Akero Therapeutics Inc. 601 Gateway Boulevard. Suite 350. South San Francisco, California 94080. Phone 1 650 487-6488. Industry Biotechnology Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. More Details. Risk Analysis. Earnings are forecast to decline by an average of 7.5% per year for the next 3 years. Currently unprofitable and not forecast to become profitable over the next 3 years. Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical need. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate AKR-001 is an FGF21 analog with properties that has the potential to address.

Akero Therapeutics Inc: AKRO: NASDAQ: Common Stock Price Change Change Percent Stock Price Last Traded -0.54-2.01%: 26.38: 19:40:13: Open Price Low Price High Price Close Price Prev Close; 27.895: 25.505: 27.895: 26.38: 26.92: more quote information » Recent News. Date Time Source Heading; 5/24/2021: 7:03: IHNW: Featured CEO's Presenting at Emerging Growth Conference Virtually This Week: 5/24. Akero Therapeutics, Inc. AKRO is a clinical-stage cardio-metabolic company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum.

Akero Therapeutics, Inc
  • Which Ethereum wallet.
  • 3DS roms cia.
  • Nasdaq Realtime Chart.
  • Key WISO Steuer Sparbuch 2021.
  • BDSwiss Support.
  • Pitcairninseln Auswandern.
  • Sylt Take Away.
  • Aktien API Java.
  • Eye of Horus Online Casino Bonus ohne Einzahlung.
  • Graphic design Studio free.
  • What is the output of a cryptographic hash function means?.
  • Erzieherin Ausbildung Gehalt.
  • Goldkurs Österreich aktuell.
  • OCC strategy TradingView.
  • MessageBird Singapore.
  • Font Awesome bullet.
  • Gemini Project.
  • Nishua NFX 2 Visier.
  • Glassnode Bitcoin balance on exchanges.
  • How to use Matic.
  • Coding Horror.
  • Red Bull Shop Wien.
  • Нефть прогноз на завтра.
  • Ombi v4 docker.
  • 3DS roms cia.
  • SAS pilot.
  • Kubuntu vs kde neon vs manjaro.
  • Opposite of FOMO.
  • Silber kaufen Berlin.
  • Degussa sonne/mond goldhandel gmbh erfahrungen.
  • Moon Active Ltd.
  • Manim Mac.
  • VOLGAZ Vin Mousseux.
  • Run it Once leaderboard.
  • Fortnite Shop übermorgen.
  • How to download Komodo.
  • BDO Forum.
  • Cryptocoryne aponogetifolia.
  • Reddit gaming PC.
  • Casino Guru Paysafecard.
  • S3rl now that i ve found you.